Xencor (XNCR) Enterprise Value (2013 - 2026)
Xencor (XNCR) posted quarterly Enterprise Value of -$384.4 million for Q1 2026, down 334.1% year-over-year from $164.2 million in Q1 2025, and up 11.68% quarter-over-quarter from -$435.2 million in Q4 2025.
Xencor (XNCR) Enterprise Value (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Enterprise Value for 14 consecutive years, with -$384.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 334.1% year-over-year to -$384.4 million; the TTM figure through Mar 2026 stood at -$384.4 million (down 334.1% YoY), while the FY2025 annual figure was -$435.2 million, up 4.01% from the prior year.
- Enterprise Value advanced to -$384.4 million in Q1 2026 per XNCR's latest filing, from -$435.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$60.8 million in Q2 2024 and bottomed at -$551.2 million in Q4 2023.
- Historically, Enterprise Value has averaged -$238.5 million across 5 years, with a median of -$112.1 million in 2023.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 79.54% — and 2025, when it slumped 563.28%.
- Xencor's Enterprise Value stood at -$96.4 million in 2022, then sank by 471.92% to -$551.2 million in 2023, then climbed by 17.73% to -$453.4 million in 2024, then gained by 4.01% to -$435.2 million in 2025, then rose by 11.68% to -$384.4 million in 2026.
- Business Quant data shows XNCR's Enterprise Value at -$384.4 million in Q1 2026, -$435.2 million in Q4 2025, and -$112.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | -377.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -377.82 Mn |
| Mar 31, 2026 | -384.38 Mn |
| Dec 31, 2025 | -435.23 Mn |
| Sep 30, 2025 | -112.55 Mn |
| Jun 30, 2025 | -403.43 Mn |
| Mar 31, 2025 | -88.55 Mn |
| Dec 31, 2024 | -453.43 Mn |
| Sep 30, 2024 | -467.01 Mn |
| Jun 30, 2024 | -60.82 Mn |
| Mar 31, 2024 | -75.91 Mn |
| Dec 31, 2023 | -551.18 Mn |
| Sep 30, 2023 | -465.56 Mn |
| Jun 30, 2023 | -74.71 Mn |
| Mar 31, 2023 | -112.10 Mn |
| Dec 31, 2022 | -96.37 Mn |
| Sep 30, 2022 | -84.84 Mn |
| Jun 30, 2022 | -76.30 Mn |
| Mar 31, 2022 | -111.70 Mn |
| Dec 31, 2021 | -180.34 Mn |
| Sep 30, 2021 | -88.78 Mn |